The unique and selective DRD2-selective partial agonist (−)-IHCH7041 may provide the medical community with chemical tools for exploring signaling pathways that counteract the efficacy and side effects of psychiatric disorders such as depression (Chen et al., 2022). The gene discussed is DRD2; the disease is depressive disorder.